LONDON, Dec 19 (Reuters) - Shares in Vernalis fell sharply on Friday as Swiss drugmaker Novartis stopped development work on a drug licensed from the British biotech company 10 years ago. Vernalis said Novartis had handed back rights to AUY922 after studying it as a treatment for a range of
Read moreTSB Banking: Shore Capital reiterates buy with a target price for 325p. Vernalis: Canaccord Genuity ups target to 66p from 56p and reiterates buy. Aggreko: Panmure Gordon and Investec reiterate hold. Gemfields: Numis initiates coverage with a buy recommendation and 70p target price. Ithaca Energy
Read more